---
schema_version: "secwatch.filing_event.v1"
accession: "0001100682-25-000019"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T06:56:46.934302+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Charles River Q1 revenue down 2.7% to $984.2M; raises FY2025 guidance

## Summary
- GAAP EPS $0.50 vs $1.30 YoY; Non-GAAP EPS $2.34 vs $2.27, up 3.1%.
- Revenue decline across all segments: RMS -3.5%, DSA -2.1%, Manufacturing -3.6%.
- DSA net bookings reached highest level in two years, signaling demand stabilization.
- Raised FY2025 Non-GAAP EPS guidance to $9.30-$9.80 from $9.10-$9.60; organic revenue growth range narrowed.
- Repurchased $350M of common stock in Q1; $549.3M remaining on $1B authorization.

## SEC filing metadata
- accession: 0001100682-25-000019
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000110068225000019/0001100682-25-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000110068225000019/crl-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001100682-25-000019
- JSON: https://secwatch.observer/filing/0001100682-25-000019.json
- Plain text: https://secwatch.observer/filing/0001100682-25-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.